As scrutiny on insulin prices continues to grow, drug makers and other stakeholders are looking for ways to address the problem for patients, while also having concrete initiatives to show legislators investigating pricing practices.
Sanofi was the latest to announce an expanded cost-savings program April 10 that will allow diabetics in the US to pay $99 for up to 10 boxes of pens...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?